Jazz Pharmaceuticals Affirms FY2026 Sales Guidance of $4.250B-$4.500B vs $4.445B Est

Benzinga Newsdesk www.benzinga.com Negative 62.3%

Neg 62.3% Neu 0% Pos 0%

Jazz Pharmaceuticals (NASDAQ:JAZZ) affirms FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.250 billion-$4.500 billion vs $4.445 billion estimate.